Data regarding the therapeutic response to EGFR TKIs in the context of uncommon del19 mutations are still debated in NSCLC [14,15,16], as responses may vary based on the specific nature of the del19 alteration, which could modulate the receptor’s affinity for EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.